The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset

Neurosci Lett. 1988 Nov 11;93(2-3):275-80. doi: 10.1016/0304-3940(88)90095-x.

Abstract

Administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets induced persistent motor deficits. Administration of the D1 agonist SKF 38393 (2.5-20 mg/kg, i.p.) caused a dose-dependent increase of this akinesia. Administration of the D2 agonist LY 171555 (0.3 mg/kg, i.p.) reversed the motor deficits induced by MPTP treatment. Pretreatment of animals with SKF 38393 (2.5-20 mg/kg, i.p.) caused dose-dependent inhibition of the anti-parkinsonian action of LY 171555 (0.3 mg/kg i.p.). In primates SKF 38393 does not reverse motor deficits induced by MPTP and inhibits the actions of a D2-agonist.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
  • Animals
  • Benzazepines / pharmacology*
  • Callithrix
  • Dopamine Agents* / antagonists & inhibitors
  • Dopamine Agents* / pharmacology
  • Ergolines / antagonists & inhibitors*
  • Female
  • Male
  • Motor Activity / drug effects*
  • Pyridines
  • Quinpirole

Substances

  • Benzazepines
  • Dopamine Agents
  • Ergolines
  • Pyridines
  • Quinpirole
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine